SH2B3 and ovarian cancer: In contrast to hematologic malignancies, SH2B3 was reported to activate the JAK/STAT3 and ERK1/2 pathways to promote the progression of triple-negative breast cancer (Lv et al., 2020) and act as a positive signal transduction regulator in ovarian cancers (Ding et al., 2015).